# IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoid-based-therapy-alzheimer-agitation-phase-2-trial/ > **Published:** 2026-02-23T14:07:37-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:14:35-04:00 > **Clinical Summary:** The Phase 2 CALMA trial expands clinical sites for cannabinoid-based therapy Alzheimer agitation, advancing cannabis treatment options in dementia care. --- CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. NeurologyResearchAgingSafetyTHC Why This Matters If you or a loved one is living with Alzheimer’s-related agitation, the expansion of this clinical trial means more opportunities to access investigational [cannabinoid therapy](https://cedclinic.com/unknown-cannabinoid-receptor-brain-damage-relief/) and brings us closer to having FDA-reviewed evidence for cannabis-based treatment options in dementia care. Clinical Summary The expansion of clinical trial sites for IGC Pharma’s Phase 2 CALMA trial investigating cannabinoid-based therapy for Alzheimer’s-associated agitation represents a meaningful step in building the evidence base for [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) in neurodegenerative disease. Alzheimer’s-related behavioral symptoms like agitation and aggression are notoriously difficult to manage with conventional medications, and cannabinoid therapies have shown early promise in addressing neuroinflammation and behavioral dysregulation through [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) modulation. Adding multi-site clinical networks to this trial increases enrollment capacity and brings us closer to the rigorous data needed to move cannabinoid therapies from anecdotal use into standardized clinical practice for dementia care. Dr. Caplan’s Take “We have been using cannabinoids clinically for agitation in dementia patients for years with promising results, and it is past time that formal trials catch up to what many of us are already seeing in practice.” Clinical Perspective [Cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) in Alzheimer’s disease is advancing, with a Phase 2 trial expanding its clinical site network to accelerate enrollment and data collection. Agitation in Alzheimer’s patients is one of the most distressing symptoms for both patients and caregivers, and current pharmaceutical options like antipsychotics carry significant risks including increased mortality. The [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) is deeply involved in neuroinflammation, synaptic plasticity, and behavioral modulation, making it a logical therapeutic target in neurodegenerative disease. What excites me most as a clinician is that we are finally seeing the kind of multi-site, controlled trial infrastructure that can produce data robust enough to shift prescribing guidelines. For the thousands of families I work with who are already exploring cannabinoids for their loved ones with dementia, this research cannot come soon enough. Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+IGC+Pharma+Adds+Visionary+Investigators+Network+as+Clinical+Site+to+Phase+2+CALMA+Trial+%40drcaplan&url=https%3A%2F%2Fwww.newswire.com%2Fnews%2Figc-pharma-adds-visionary-investigators-network-as-clinical-site-to-phase-2) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.newswire.com%2Fnews%2Figc-pharma-adds-visionary-investigators-network-as-clinical-site-to-phase-2) [🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+IGC+Pharma+Adds+Visionary+Investigators+Network+as+Clinical+Site+to+Phase+2+CALMA+Trial+%E2%80%94+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.newswire.com%2Fnews%2Figc-pharma-adds-visionary-investigators-network-as-clinical-site-to-phase-2) [📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/) [📝 Read more on Substack](https://substack.com/@doctorapproved) [🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) 📰 Source: [https://www.newswire.com/news/igc-pharma-adds-visionary-investigators-network-as-clinical-site-to-phase-2](https://www.newswire.com/news/igc-pharma-adds-visionary-investigators-network-as-clinical-site-to-phase-2) Further Reading Evidence Watch[The Brain Science Behind the Munchies – Nautilus Magazine](https://cedclinic.com/cannabis-appetite-stimulation-neuroscience/) Evidence WatchIGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial CED Clinic Blog[Endocannabinoid System in Older Adults: 7 Essential Insights](https://cedclinic.com/endocannabinoid-system-older-adults/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabinoid-Based Therapies Linked to Reduced Agitation in Alzheimer's Patients, Meta …](https://cedclinic.com/cannabinoid-based-therapies-linked-to-reduced-agitation-in-alzheimers-patients-meta/) Explore meta-analyses linking cannabinoid-based therapies to reduced agitation in Alzheimer's patients, highlighting emerging clinical evidence. [Read More](https://cedclinic.com/cannabinoid-based-therapies-linked-to-reduced-agitation-in-alzheimers-patients-meta/) [Cannabis-Based Therapies Improve Alzheimer's-Related Agitation](https://cedclinic.com/cannabis-based-therapies-improve-alzheimers-related-agitation/) Review clinical insights on how [cannabis-based therapies](https://cedclinic.com/cannabinoids-inhibit-keratinocyte-proliferation-non-cb1-cb2/) are improving agitation symptoms in Alzheimer's disease. [Learn More](https://cedclinic.com/cannabis-based-therapies-improve-alzheimers-related-agitation/) [New Clinical Insights on Cannabis and Patient Outcomes](https://cedclinic.com/new-clinical-insights-on-cannabis-and-patient-outcomes/) Discover recent clinical findings on cannabis therapies and their impact on patient outcomes across neurological conditions. [Explore Now](https://cedclinic.com/new-clinical-insights-on-cannabis-and-patient-outcomes/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).